BiomX Inc. (NYSEAMERICAN:PHGE – Free Report) – Equities researchers at HC Wainwright upped their Q3 2025 EPS estimates for BiomX in a report issued on Wednesday, August 20th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.32) for the quarter, up from their prior estimate of ($0.37). HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for BiomX’s current full-year earnings is ($2.77) per share. HC Wainwright also issued estimates for BiomX’s Q4 2025 earnings at ($0.36) EPS and FY2025 earnings at ($1.18) EPS.
BiomX Stock Performance
Shares of PHGE stock opened at $0.5468 on Friday. The company has a fifty day simple moving average of $0.46. The stock has a market cap of $14.51 million, a P/E ratio of -0.40 and a beta of 1.42. BiomX has a 52 week low of $0.34 and a 52 week high of $1.6196.
About BiomX
BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).
See Also
- Five stocks we like better than BiomX
- Where Do I Find 52-Week Highs and Lows?
- Royal Caribbean Earnings Beat Fuels Strong 2025 Outlook
- Why is the Ex-Dividend Date Significant to Investors?
- Alphabet’s Breakout Potential: From Laggard to AI Leader
- Using the MarketBeat Stock Split Calculator
- TJX Stock Price Hits Fresh High, Signals More Highs to Follow
Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with MarketBeat.com's FREE daily email newsletter.
